For your patients with
hereditary angioedema (HAE)...
CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6.
Start with HAE attack prevention
Not real patients.
CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6.
Start with HAE attack prevention.
This overview of CINRYZE can help patients understand how CINRYZE works, whether a C1-INH preventive therapy might be right for them, and what to expect from therapy.
After you teach patients how to self-administer CINRYZE therapy, share this brochure which features step-by-step illustrated instructions, for additional at-home support.
Takeda advises the patient to receive training from a healthcare professional prior to self-administration.Takeda advises the patient and/or caregiver(s) to receive training from a healthcare professional prior to self-administration.
Supporting patients with HAE and prescribers for over 16 years
Our services include:
*To be eligible, your patient must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply. Contact us for more details.
Need assistance?
Our support specialists are never more than a tap or a call away—1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM ET.
Need to enroll your patient? Visit TakedaPatientSupport.com/HCP for more information. You can enroll your patient by faxing the completed Start Form.
If English is not your patient’s preferred language, we may be able to assist them in a language of their choosing.